Debating the Significance of MRD in Blood Cancers vs Initial Patient CharacteristicsSeptember 28th 2022
In the myeloma space, minimal residual disease negativity is prognostic of progression-free survival in relapsed or refractory patients. In leukemia, the biomarker combined with other prognostication techniques provides complex information that is clinically relevant.
BPDCN: Epidemiology, Pathophysiology, and DiagnosisSeptember 27th 2022
Opening the discussion on the management of BPDCN, an expert panel consisting of two hematologist-oncologists and a pathologist, considers the causes, incidence and diagnostic approach to this rare disease.
FDA Approves Eflapegrastim for Chemotherapy-Induced NeutropeniaSeptember 9th 2022
The FDA has approved eflapegrastim-xnst injection for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs linked with clinically significant incidence of febrile neutropenia.
FDA Clears IND for CNTY-101 in Relapsed/Refractory CD19 Positive B-cell MalignanciesAugust 29th 2022
An investigational new drug application has been accepted by the FDA allowing for the start of a phase 1 trial to evaluate the tolerability of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies
Couriel Assesses the Available Data for Treatment of Acute GVHDAugust 26th 2022
During a Targeted Oncology case-based roundtable event, Daniel R. Couriel, MD, MS, MBA, discussed how to predict risk of acute graft-vs-host-disease and manage its effects on patients with hematologic malignancies.
FDA Grants Priority Review to Application for Omidubicel for Blood Cancers in Need of TransplantAugust 2nd 2022
Pivotal phase 3 result have led the FDA to accept a biologics license applications for omidubicel as treatment of patients with blood cancers requiring allogenic hematopoietic stem cell transplant. The applications has been accepted for priority review.
Safah Explores Risk Factors and Poststeroid Treatment for GVHDJuly 26th 2022
During a Targeted Oncology case-based roundtable event, Hana F. Safah, MD, discussed risk factors for acute graft-versus-host disease and data supporting treatment for steroid-refractory disease.
FDA Grants Fast Track Designation to Eltanexor for R/R Myelodysplastic SyndromeJuly 21st 2022
Following positive phase 1 study results for eltanexor monotherapy in patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndrome, the FDA has granted the drug fast track status.
Bishop Reviews Risk Assessment and Treatment for GVHDJuly 6th 2022
Michael R. Bishop, MD, discussed a patient with graft-versus-host disease who first underwent a myeloablative conditioning regimen and peripheral blood stem-cell matched hematopoietic cell transplant as treatment.
Chao Discusses Stratifying and Treating Patients With Graft-Vs-Host DiseaseJune 27th 2022
During a Targeted Oncology case-based roundtable event, Nelson Jen An Chao, MD, discussed risk management and treatment of patients with steroid-refractory acute graft-versus-host-disease as well as chronic graft-versus-host disease.
Next-Generation Treatments for Blood Cancers: Improved Outcomes in the ForecastJune 16th 2022
The excitement surrounding advances and improved outcomes in very difficult-to-treat diseases is palpable. Yet the complexities of these therapies also bring their own complications.
Adaptive NK Cell Platform Shows Safety for Hematological MalignanciesJune 11th 2022
Jeffrey S. Miller, MD, discusses the findings of a study of the Tri-Specific Killer Engager platform for the activation of natural killer cells for the treatment of refractory acute myeloid leukemia and other cancers.
Hyper-CVAD With Blinatumomab and Inotuzumab Shows High Efficacy in Ph-Negative B-Cell ALLJune 4th 2022
The probability of minimal residual disease negativity and complete remission in patients who received hyper-CVAD with blinatumomab and inotuzumab is higher compared with hyper-CVAD and blinatumomab alone.
Roundtable Discussion: Early Treatment Options and Policies Discussed for Acute GVHDJune 3rd 2022
During a Targeted Oncology case-based roundtable event, Pashna N. Munshi, MD, discussed the case of a patient who developed maculopapular rash 22 days following hematopoietic stem cell transplantion.
Simplifying CAR T-Cell Manufacturing for R/R B-Cell Non-Hodgkin’s LymphomaMay 19th 2022
Manali Kamdar, MD, MBBS, discusses the background on a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell non-Hodgkin’s lymphoma.